Last reviewed · How we verify

Paclitaxel Micelles for Injection — Competitive Intelligence Brief

Paclitaxel Micelles for Injection (Paclitaxel Micelles for Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule stabilizer. Area: Oncology.

phase 3 Taxane; microtubule stabilizer β-tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Paclitaxel Micelles for Injection (Paclitaxel Micelles for Injection) — Shanghai Yizhong Pharmaceutical Co., Ltd.. Paclitaxel micelles stabilize microtubules by binding to β-tubulin, preventing their depolymerization and halting cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Paclitaxel Micelles for Injection TARGET Paclitaxel Micelles for Injection Shanghai Yizhong Pharmaceutical Co., Ltd. phase 3 Taxane; microtubule stabilizer β-tubulin
ZENTEL and Vitamin A Soft Capsules ZENTEL and Vitamin A Soft Capsules Chengdu Maternal and Children's Health Care Hospital marketed Anthelmintic + Vitamin supplement β-tubulin (albendazole component)
Paclitaxel (albumin-bound) Paclitaxel (albumin-bound) Dai, Guanghai marketed Taxane; microtubule stabilizer β-tubulin (microtubule)
Paclitaxel protein bound Paclitaxel protein bound Barts & The London NHS Trust marketed Taxane; microtubule stabilizer β-tubulin (microtubule)
Docetaxel or albumin paclitaxel Docetaxel or albumin paclitaxel Shandong Cancer Hospital and Institute marketed Taxane; microtubule-stabilizing chemotherapy agent β-tubulin (microtubule)
Docetaxel (D) Docetaxel (D) BeyondSpring Pharmaceuticals Inc. marketed Taxane; microtubule stabilizer β-tubulin
VLI VLI Spectrum Pharmaceuticals, Inc marketed Vinca alkaloid β-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule stabilizer class)

  1. Sanofi · 2 drugs in this class
  2. Aravive, Inc. · 1 drug in this class
  3. Athenex, Inc. · 1 drug in this class
  4. Barts & The London NHS Trust · 1 drug in this class
  5. BeyondSpring Pharmaceuticals Inc. · 1 drug in this class
  6. Bio-Thera Solutions · 1 drug in this class
  7. Dai, Guanghai · 1 drug in this class
  8. Fujian Medical University · 1 drug in this class
  9. Guangzhou Double Bioproducts Co., Ltd · 1 drug in this class
  10. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paclitaxel Micelles for Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-micelles-for-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: